Lisinopril anhydrous is an angiotensin converting enzyme inhibitor. The mechanism of action of lisinopril anhydrous is as an angiotensin-converting enzyme inhibitor. One of the angiotensin-converting enzyme inhibitors (ace inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.
Lisinopril anhydrous is the anhydrous form of the long-acting angiotensin-converting enzyme (ace) inhibitor lisinopril with antihyper- tensive activity. Lisinopril, a synthetic peptide derivative, competitively binds to and inhibits ace, thereby blocking the conversion of angiotensin I to angiotensin ii. This prevents the potent vasoconstrictive actions of angiotensin ii and results in vasodilation. Lisinopril also decreases angiotensin ii-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow.

Lisinopril anhydrous is an angiotensin converting enzyme inhibitor. The mechanism of action of lisinopril anhydrous is as an angiotensin-converting enzyme inhibitor. One of the angiotensin-converting enzyme inhibitors (ace inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.
Lisinopril anhydrous is the anhydrous form of the long-acting angiotensin-converting enzyme (ace) inhibitor lisinopril with antihyper- tensive activity. Lisinopril, a synthetic peptide derivative, competitively binds to and inhibits ace, thereby blocking the conversion of angiotensin I to angiotensin ii. This prevents the potent vasoconstrictive actions of angiotensin ii and results in vasodilation. Lisinopril also decreases angiotensin ii-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow.